Market Access

By Nicole May, Research Analyst The burden of proving drugs’ cost-effectiveness data falls in part to health outcomes liaisons (HOLs) who work between pharmaceutical companies and payers to get their company’s drugs onto formularies.  HOLs...

According to the American Hospital Association, hospitals nationwide remain liable for up to $41.1 billion in unpaid healthcare costs annually.  This cost is up from the recorded amount of outstanding costs in 2010 ($39.3 billion).  Currently, Jack Hadley, senior...

Fresh news out of India this week is likely to add to pharmaceutical companies' concerns about pricing and sales in emerging markets.  Despite indications in February that compulsory licensing may be coming to an end, on March 18, BDR Pharmaceuticals applied for...

Over the past few years, political, social and economic upheavals worldwide have thrust change on the life sciences landscape — and forced pricing teams to work overtime.  Today, these teams must deal with a series of events and trends that each have some effect...

Growing up, siblings have an unspoken rule that  if one received something or was allowed to do something that another wasn’t, instantly, life became “unfair” for the other party.  The smaller the age differential between the siblings, the more unfair the...

In this harsh reimbursement environment, payers are looking beyond a drug’s efficacy and to its cost-effectiveness when approving drugs for their formularies.  To adapt to new payer demands, pharma companies are incorporating health economics and outcomes research...

In a recent study on HEOR teams, we found that accessing quality data for HEOR analysis is a challenge for companies worldwide. As shown in the accompanying Figure, on a scale of 1 to 10 (with 10 being the most difficult), US companies rated accessing quality data...

Traditionally, health outcomes liaisons (HOLs) and medical science liaisons (MSLs) represent two different areas of expertise. Both jobs serve an important role: to provide an educational connection between industry leaders and key stakeholders. The former serves...

Before US managed markets teams approach payers, they need to understand the different payer groups. All groups — Medicare and Medicaid, insurance companies, specialty pharmacies, hospitals, etc. — share the same fundamental function: to sift through the many...

Companies are increasingly turning to patient-reported outcomes (PROs) as payers look for additional outcomes data when making reimbursement decisions. Our recent reports, “Market Access Management: Building Teams that Deliver Value to Payers” and “Health...